RTOG 0920 - A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Clinical Trial Information
Trial Contact: Quintiliani, Jennifer
Trial Phone: 321.843.2026
IRB No: RTOG 0920
Protocol Abbrev: RTOG 0920
Principal Investigator: Rafael R. Manon, MD
Sub Investigators: Johnson, Tirrell MD; Neely, Lindsey ARNP; Rineer, Justin MD; Tseng, Jennifer MD
Phase: Drug: Phase III
Age Group: Adult
Secondary Protocol No: RTOG 0920
Applicable Disease Sites: Head and Neck
Therapies Involved: Biological: cetuximab Radiation: intensity-modulated radiation therapy
ClinicalTrials.gov ID: NCT00956007
This trial is studying radiation therapy to see how well it works compared with radiation therapy given together with cetuximab in treating patients who have undergone surgery for head and neck cancer.
Must have histologically proven diagnosis of squamous cell carcinoma (including variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma NOS, etc.) of the head/neck (oral cavity, oropharynx or larynx). Must have Clinical stage T1, N1-2 or T2-4a, N0-2, M0 including no distant metastases. Must have undergone gross total resection of the primary tumor with curative intent within the past 7 weeks.